Stephens Inc’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $310K | Buy |
+2,356
| New | +$313K | ﹤0.01% | 1023 |
|
|
2024
Q3 | – | Sell |
-2,679
| Closed | -$369K | – | 1326 |
|
|
2024
Q2 | $369K | Buy |
2,679
+121
| +5% | +$16.6K | 0.01% | 918 |
|
|
2024
Q1 | $353K | Sell |
2,558
-4,330
| -63% | -$591K | 0.01% | 944 |
|
|
2023
Q4 | $908K | Buy |
6,888
+955
| +16% | +$110K | 0.02% | 559 |
|
|
2023
Q3 | $667K | Hold |
5,933
| – | – | 0.01% | 631 |
|
|
2023
Q2 | $559K | Buy |
5,933
+49
| +0.8% | +$4.79K | 0.01% | 703 |
|
|
2023
Q1 | $596K | Sell |
5,884
-166
| -3% | -$17.3K | 0.01% | 667 |
|
|
2022
Q4 | $723K | Hold |
6,050
| – | – | 0.01% | 586 |
|
|
2022
Q3 | $643K | Sell |
6,050
-84
| -1% | -$8.52K | 0.01% | 620 |
|
|
2022
Q2 | $598K | Buy |
6,134
+47
| +0.8% | +$4.34K | 0.01% | 667 |
|
|
2022
Q1 | $571K | Buy |
6,087
+561
| +10% | +$47.5K | 0.01% | 756 |
|
|
2021
Q4 | $471K | Sell |
5,526
-770
| -12% | -$70.8K | 0.01% | 870 |
|
|
2021
Q3 | $604K | Buy |
6,296
+524
| +9% | +$49.5K | 0.01% | 801 |
|
|
2021
Q2 | $562K | Buy |
5,772
+116
| +2% | +$11.1K | 0.01% | 830 |
|
|
2021
Q1 | $550K | Buy |
+5,656
| New | +$593K | 0.01% | 810 |
|
|
2020
Q4 | – | Sell |
-5,583
| Closed | -$537K | – | 1248 |
|
|
2020
Q3 | $537K | Buy |
5,583
+271
| +5% | +$31.3K | 0.01% | 714 |
|
|
2020
Q2 | $648K | Hold |
5,312
| – | – | 0.01% | 635 |
|
|
2020
Q1 | $460K | Buy |
+5,312
| New | +$520K | 0.01% | 669 |
|
|
2019
Q4 | – | Sell |
-5,340
| Closed | -$481K | – | 1182 |
|
|
2019
Q3 | $481K | Buy |
5,340
+840
| +19% | +$78.5K | 0.01% | 767 |
|
|
2019
Q2 | $380K | Hold |
4,500
| – | – | 0.01% | 832 |
|
|
2019
Q1 | $396K | Hold |
4,500
| – | – | 0.01% | 819 |
|
|
2018
Q4 | $321K | Hold |
4,500
| – | – | 0.01% | 823 |
|
|
2018
Q3 | $553K | Buy |
+4,500
| New | +$511K | 0.01% | 755 |
|
|
2017
Q3 | – | Sell |
-4,500
| Closed | -$207K | – | 813 |
|
|
2017
Q2 | $207K | Buy |
+4,500
| New | +$218K | 0.01% | 785 |
|
|
2016
Q4 | – | Sell |
-4,500
| Closed | -$228K | – | 814 |
|
|
2016
Q3 | $228K | Hold |
4,500
| – | – | 0.01% | 670 |
|
|
2016
Q2 | $205K | Buy |
+4,500
| New | +$207K | 0.01% | 674 |
|
|
2016
Q1 | – | Sell |
-5,100
| Closed | -$289K | – | 782 |
|
|
2015
Q4 | $289K | Hold |
5,100
| – | – | 0.01% | 555 |
|
|
2015
Q3 | $203K | Buy |
5,100
+50
| +1% | +$2.42K | 0.01% | 645 |
|
|
2015
Q2 | $241K | Buy |
+5,050
| New | +$214K | 0.01% | 659 |
|
Other funds holding NBIX
VPM
VCM
Stephens Inc's NBIX Position: Q1 2026 in Review
Stephens Inc opened a new position in Neurocrine Biosciences (NBIX) in Q1 2026: 2,356 shares worth $310K. The stake represents ﹤0.01% of the portfolio and ranks #1023 among its holdings. This is a return to the name: Stephens Inc previously reported a position in NBIX as recently as Q2 2024.
Stephens Inc first reported a position in NBIX in Q2 2015 and has held it in 29 quarters since. The position peaked at $908K in Q4 2023. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Stephens Inc held 2,356 shares of Neurocrine Biosciences worth $310K as of Q1 2026.
- Neurocrine Biosciences was a new Stephens Inc position in Q1 2026.
- Neurocrine Biosciences made up ﹤0.01% of Stephens Inc's portfolio in Q1 2026, its #1023 holding.
- Stephens Inc first reported a position in Neurocrine Biosciences in Q2 2015 and has held it in 29 quarters since.
- Stephens Inc's Neurocrine Biosciences position peaked at $908K in Q4 2023.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Stephens Inc's 13F filing for Q1 2026, filed 28 Apr 2026.